Bachsais Meriem, Naddaf Nadim, Yacoub Daniel, Salti Suzanne, Alaaeddine Nada, Aoudjit Fawzi, Hassan Ghada S, Mourad Walid
Laboratoire d'Immunologie Cellulaire et Moléculaire, Centre Hospitalier de l'Université de Montréal, 900 rue Saint-Denis, Tour Viger, Room 10-482, Montréal, QC, Canada.
Department of Pathology, 11-5076, Faculty of Medicine, St Joseph University, Beirut, Lebanon.
PLoS One. 2016 Jul 8;11(7):e0158987. doi: 10.1371/journal.pone.0158987. eCollection 2016.
CD154, a critical regulator of the immune response, is usually associated with chronic inflammatory, autoimmune diseases as well as malignant disorders. In addition to its classical receptor CD40, CD154 is capable of binding other receptors, members of the integrin family, the αIIbβ3, αMβ2 and α5β1. Given the role attributed to integrins and particularly the β1 integrins in inhibiting apoptotic events in normal as well as malignant T cells, we were highly interested in investigating the role of the CD154/α5β1 interaction in promoting survival of malignant T cells contributing as such to tumor development and/or propagation. To support our hypothesis, we first show that soluble CD154 binds to the T-cell acute lymphoblastic leukemia cell line, Jurkat E6.1 in a α5β1-dependent manner. Binding of soluble CD154 to α5β1 integrin of Jurkat cells leads to the activation of key survival proteins, including the p38 and ERK1/2 mitogen-activated protein kinases (MAPKs), phosphoinositide 3 kinase (PI-3K), and Akt. Interestingly, soluble CD154 significantly inhibits Fas-mediated apoptosis in T cell leukemia-lymphoma cell lines, Jurkat E6.1 and HUT78 cells, an important hallmark of T cell survival during malignancy progression. These anti-apoptotic effects were mainly mediated by the activation of the PI-3K/Akt pathway but also involved the p38 and the ERK1/2 MAPKs cascades. Our data also demonstrated that the CD154-triggered inhibition of the Fas-mediated cell death response was dependent on a suppression of caspase-8 cleavage, but independent of de novo protein synthesis or alterations in Fas expression on cell surface. Together, our results highlight the impact of the CD154/α5β1 interaction in T cell function/survival and identify novel targets for the treatment of malignant disorders, particularly of T cell origin.
CD154是免疫反应的关键调节因子,通常与慢性炎症、自身免疫性疾病以及恶性疾病相关。除了其经典受体CD40外,CD154还能够结合其他受体,即整合素家族成员αIIbβ3、αMβ2和α5β1。鉴于整合素尤其是β1整合素在抑制正常及恶性T细胞凋亡事件中的作用,我们对研究CD154/α5β1相互作用在促进恶性T细胞存活从而推动肿瘤发展和/或增殖方面的作用非常感兴趣。为支持我们的假设,我们首先表明可溶性CD154以α5β1依赖的方式与T细胞急性淋巴细胞白血病细胞系Jurkat E6.1结合。可溶性CD154与Jurkat细胞的α5β1整合素结合会导致关键存活蛋白的激活,包括p38和ERK1/2丝裂原活化蛋白激酶(MAPK)、磷酸肌醇3激酶(PI-3K)和Akt。有趣的是,可溶性CD154显著抑制T细胞白血病-淋巴瘤细胞系Jurkat E6.1和HUT78细胞中Fas介导的凋亡,这是恶性肿瘤进展过程中T细胞存活的一个重要标志。这些抗凋亡作用主要由PI-3K/Akt途径的激活介导,但也涉及p38和ERK1/2 MAPK级联反应。我们的数据还表明,CD154触发的对Fas介导的细胞死亡反应的抑制依赖于对caspase-8裂解的抑制,但与从头蛋白质合成或细胞表面Fas表达的改变无关。总之,我们的结果突出了CD154/α5β1相互作用对T细胞功能/存活的影响,并确定了治疗恶性疾病特别是T细胞起源恶性疾病的新靶点。